Abstract: A rotary sensor assembly, comprising a first sensor part with a plurality of position sensor segments, and a second sensor part with a grounded contact in contact with a position sensor segment. For a current incremental rotational position a contact is in contact with an un-powered current-position sensor segment, with the neighbour segments being in a powered state. When the contact is rotated to a powered next-position position sensor segment, the next-position sensor segment becomes a new current-position sensor segment. Electronic circuitry is adapted to detect that the new current-position sensor segment is grounded and that the first and second sensor parts thereby have been rotated one increment relative to each other, and subsequently change the state of the former current-position sensor segment from un-powered to powered and the state of the new current-position sensor segment from powered to un-powered.

Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

Abstract: Drug delivery system comprising expelling means for expelling an amount of drug from a reservoir, the expelling means comprising dose setting means (11, 21, 122) allowing a user to set a dose to be expelled, and actuation means (123) for releasing the drug expelling means to expel the set dose. The dose setting means comprises a drive sleeve (22) adapted to be rotated to set a dose, and a rotatable driven member (21) arranged for being rotationally driven by the drive sleeve (22) in a slaved rotational movement by means of a torque transfer coupling between the drive sleeve (22) and the rotatable driven member (21). The system further comprises an electronically controlled capturing system for capturing data representing a property related to the amount of drug expelled from the reservoir by the expelling means, and switch means configured to initiate an action within the electronically con-trolled capturing system upon occurrence of the slaved rotational movement.

Abstract: A needle cannula (100) and a method for producing a needle cannula comprising providing a needle cannula tube (10) with an end portion (30). The end portion (30) comprises an outer surface, and a given type of steel comprising carbon (C) in 0.07 to 0.15% by mass, silicon (Si) in 0.50 to 1.00% by mass, manganese (Mn) in 5.0 to 7.5% by mass, phosphorus (P) in 0 to 0.030% by mass, sulfur (S) in less than or equal to 0.015% by mass, chromium (Cr) in 17.5 to 19.5% by mass, nickel (Ni) in 6.5 to 8.5% by mass, and nitrogen (N) in 0.20 to 0.30% by mass. The method further comprises establishing an electrochemical reaction to remove material from the outer surface of the end portion (30), and thereby providing a needle cannula (100) with a tapered end portion.

Abstract: The present invention concerns a medical injection device for apportioning set doses of a preservative containing liquid drug. The injection device comprises a housing supporting a cartridge containing the preservative containing liquid drug and a needle cannula for transferring the liquid drug from the cartridge and through the skin of a user. Further, a needle shield which is axially movable in relation to the housing is also present. The axially movable shield carries a cleaning reservoir for cleaning at least the tip of the needle cannula between subsequent injections and the cleaning reservoir is preferably filled with preservative containing liquid drug directly from the cartridge upon initiation of the injection device. In order to eliminate any overpressure being built up inside the cleaning reservoir during the filling process, the cleaning reservoir is provided with an outlet configured to be permanently sealed by a user activated operation.

Abstract: A sensor assembly comprising a first rotary sensor part with a plurality of individual electrically conducting axial position sensor segments arranged in a circumferential pattern, and a second rotary sensor part arranged rotationally relative to the first portion and comprising a plurality of circumferentially arranged electrically interconnected axial position contacts adapted to be arranged in contact with the axial position sensor segments. The assembly further comprises actuator means for axially moving the axial position contacts between a connected and a dis-connected position, wherein the axial position contacts and the axial position sensor segments are arranged such that for a given rotational position at least two axial position contacts each are in contact with a different axial position sensor segment.

Abstract: A cartridge comprising a generally cylindrical cartridge main body with a proximal edge portion having a circumferential inner surface and a proximal opening surrounded by a circumferential edge, a piston slidable received therein, and a ring-formed code member attached to the circumferential edge portion and comprising an axially extending mounting portion in engagement with the edge portion circumferential inner surface, a flange portion having a distally facing mounting surface in engagement with the circumferential edge and a proximally facing stop surface, and a drive opening allowing a piston rod to engage the piston proximal surface, wherein the flange portion radially extends within the circumferential boundaries of the cartridge main body.

Abstract: The present invention relates to solid compositions comprising a GLP-1 peptide and a delivery agent, such as SNAC, as well as uses thereof.

Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1(7-37) (SEQ ID NO: 1); a second K residue at a position corresponding to position T of GLP-1(7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1(7-37); wherein the first K residue is designated K27, and the second K residue is designated KT; which derivative comprises two albumin binding moieties attached to K27 and KT, respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from HOOC—(CH2)2—CO— and HOOC—C6H4—O—(CH2)y—CO—; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula —NH—(CH2)2—(O—(CH2)2)k—O—(CH2)n—CO—, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or este

Abstract: The present invention provides a drug injection device (100) comprising a first element (140) and a second element (103) configured to undergo unidirectional movement relative to each other corresponding to an action performed on or by the drug injection device (100), wherein the first element (140) comprises a plurality of serially disposed protrusions (143), wherein the second element (103) comprises first and second deflectable transducers (103a/153a, 103b/153b) configured for sequentially cooperating with the plurality of protrusions (143), and wherein a processor (151) is electrically connected with the first and second deflectable transducers (103a/153a, 103b/153b) to register activation signals, wherein the protrusion configuration is so disposed on the first element (140) and the first and second deflectable transducers (103a/153a, 103b/153b) are so disposed on the second element (103) that a second activation signal generated by the second deflectable transducer (103b/153b) is delayed relative to a f

Abstract: Methods of manufacturing tissue interfacing components, such as solid needles comprising one or more therapeutic agents, are disclosed. In some embodiments, a method for manufacturing a tissue interfacing component comprises compressing a granular therapeutic agent within a mold cavity of a mold to form a solid tissue interfacing component. The mold cavity may define an elongated shape extending along a longitudinal axis from an opening of the mold cavity to a distal end of the mold cavity, and the granular therapeutic agent may be compressed by moving a mold punch along the longitudinal axis towards the distal end. After compressing the granular therapeutic agent to form the solid tissue interfacing component, the tissue interfacing component may be removed from the mold and subsequently inserted into tissue to deliver the therapeutic agent to a subject.

Abstract: The present invention relates to a pre-filled disposable injection device and a needle cannula in combination. The prefilled disposable injection device (1) is made from a housing (2) containing a non-exchangeable cartridge (10) for storing a liquid drug sufficient for a number of injections. The proximal end of the pre-filled injection device (1) carries the dose setting button (3) and the distal end carries the needle cannula (20) having a lumen (21) through which the settable dose is expelled. The distal end (23) of the needle cannula (20) is covered by a telescopic needle covering shield (30) which shield (30) can operate between a first position covering the tip (24) of the needle cannula (20) and a second retracted position allowing an injection to be performed.

Abstract: An add-on device adapted to be releasably attachable to a drug delivery device, the drug delivery device comprising a first housing having a first mounting surface with a first positioning structure, and a dose setting mechanism with a dose indicator member. The add-on device comprises a second housing comprising a second mounting surface with a second positioning structure protruding from the second mounting surface and adapted to engage the first positioning structure form-fittingly when the add-on device is mounted on the drug delivery device, a mounting switch actuatable between a non-mounted and a mounted state, a cam-era opening formed in the mounting surface, the second positioning structure surrounding the camera opening, a camera adapted to capture an image of the indicator member when arranged in alignment with the camera window, wherein the mounting switch is arranged in the vicinity of the second positioning structure.

Abstract: The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.

Abstract: Described is a dipeptide comprising a non-proteogenic amino acid, methods of making such and methods of using said dipeptide in a process of making a polypeptide or protein comprising one or more non-proteogenic amino acids.

Abstract: A drug delivery device is provided comprising a housing having an exterior surface, drug ex-pelling means comprising an indicator member arranged to move corresponding to an action performed on or by the drug delivery device, and a carrier foil on which is formed or mounted an energy source, electronically controlled communication means, and a processor adapted to (i) receive input from the drug delivery device indicative of indicator member movement and (ii) control the communication means. The flexible carrier foil is mounted on the exterior of the housing, and the flexible carrier foil is covered at least in part by a sealing foil covering directly or indirectly the thereon formed or mounted components, whereby a sealed interior space for the components formed or mounted on the flexible carrier foil is formed between the housing exterior surface and the sealing foil.

Abstract: The invention relates to GLP-1 analogues and derivatives having a Trp at a position corresponding to position 8 of GLP-1(7-37), and their pharmaceutical use e.g. in the treatment of type 2 diabetes. These Trp8 compounds are very stable against degradation by DPP-IV, while maintaining the capability to bind to and activate the GLP-1 receptor. The derivatives have one or two substituents (P-L) attached to a Lys residue of the GLP-1 analogue via an optional Branching group (B), wherein P is a Protracting moiety such as a fatty diacid, and L is a linker consisting of one or more linker elements such as, for example, 8-amino-3,6-dioxaoctanoic acid. Examples of compounds of the invention include the 8W variants of liraglutide and dulaglutide.

Abstract: An add-on device adapted to be releasably attached to a drug delivery device, the drug delivery device comprising an indicator adapted to display a dose amount during dose setting, and to display the remaining dose amount to be expelled during drug expelling. The add-on device comprises an electronically controlled display adapted to display a set dose amount, a sensor assembly adapted to detect movement of the dose setting member when the add-on device is attached to a drug delivery device, a camera device adapted to capture an image of the indicator, and processor means adapted to (i) control the display dynamically to show the set dose amount based on input from the sensor assembly, and (ii) determine an expelled dose amount based on input from the camera device.

Abstract: The present invention provides a drug delivery system (1) comprising a drug delivery device (2, 3) carrying at least one reservoir (40a, 40b), and a needle unit (4) being attachable to the drug delivery device (2, 3) in axial extension thereof and adapted to establish a flow way between the at least one reservoir (40a, 40b) and a drug delivery site. The needle unit (4) comprises a needle structure (11) comprising a front needle portion (12) for entering the drug delivery site, and at least one back needle portion (13a, 13b) for insertion into the at least one reservoir (40a, 40b), and a needle shield (20).

Abstract: The invention relates to pharmaceutical compositions comprising a first type of granules and a second type of granules, wherein said first type of granules comprises a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and no GLP-1 peptide, and wherein said second type of granules comprises a GLP-1 peptide and no salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, as well as the intermediate granules, processes for the preparation of the granules and compositions, and use thereof in medicine.